Xcout IntelAnixa Biosciences, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Anixa Biosciences, Inc. among biotech companies — ranked by similarity to what Anixa Biosciences, Inc. actually does, not by market-cap band.
Subscribe to see Anixa Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
Anixa Biosciences, Inc. at a glance
Anixa Biosciences, Inc. is a biotech company headquartered in San Jose, United States. It is publicly listed (ANIX) with a market capitalisation of $118.7M. Xcout tracks 7 named people at Anixa Biosciences, Inc., including Amit Kumar (Chief Executive Officer, Chairman & Co-Chair of CBAB).
Anixa Biosciences, Inc. leadership
- Amit KumarChief Executive Officer, Chairman & Co-Chair of CBAB
- Michael J. CatelaniPresident, Chief Operating Officer, Chief Financial Officer & Corporate Secretary
- Pamela D. GarzoneChief Development Officer & Chair Breast Cancer Clinical Advisory Board
- Amit KumarDirector
- Arnold M BaskiesDirector
- Emily GottschalkDirector
1 more named person on record for Anixa Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Anixa Biosciences, Inc. competitors
Ranked by semantic similarity — how close each company is to Anixa Biosciences, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Biotechnology
Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm focuses on biotechnology research and developing treatments for viral infections and precancerous conditions.
Similar biotech company
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.
Biotechnology
Genexine, Inc. is a biotech company headquartered in Seoul, Republic of Korea. The company is focused on developing a healthier tomorrow and aims to grow into a global biotech company.
Biotechnology
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Biotechnology
CaroGen Corporation develops RNA-based artificial virus platforms and immunotherapies to treat infectious diseases and cancer. The company's pipeline includes late-stage preclinical candidates such as CARG-2020 for ovarian cancer and CARG-201 for chronic hepatitis B.
Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Similar biotech company
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Similar biotech company
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Biotechnology
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
Similar biotech company
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Biotechnology
Alixia, Inc. is a biotechnology company that develops therapeutics targeting tumor ecosystems to address cancer drug resistance and complex, chronic diseases. The company utilizes a research platform integrating biology, biophysics, computational chemistry, and clinical input to discover lead compounds that disrupt metabolic and inflammatory triggers within the tumor microenvironment.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Anixa Biosciences, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Anixa Biosciences, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →